Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic lupus erythematosus

Lupus

Volumn 24, Issue 13, 2015, Pages 1392-1399

  Tay, S H ^a,b   Cheung, P P M ^a,b   Mak, A ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

anxiety; depression; disease activity; Mood; SLE

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLEDAI; SMOKING; SOCIAL PSYCHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANXIETY; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PREVALENCE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANXIETY; DEPRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945303299     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315591026     Document Type: Article

References (48)

1. Lisnevskaia L, Murphy G, Isenberg D,. Systemic lupus erythematosus. Lancet 2014; 384: 1878-1888.
2. Bachen EA, Chesney MA, Criswell LA,. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 822-829.
3. Langosch J, Rand S, Ghosh B, et al. A clinical electrophysiological study of emotional lability in patients with systemic lupus erythematosus. J Neuropsychiatry Clin Neurosci 2008; 20: 201-209.
4. Berlit P,. Neuropsychiatric disease in collagen vascular diseases and vasculitis. J Neurol 2007; 254 (Suppl 2): II87-II89.
5. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A,. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
6. Uguz F, Kucuk A, Cicek E, Kayhan F, Tunc R,. Mood, anxiety and personality disorders in patients with systemic lupus erythematosus. Compr Psychiatry 2013; 54: 341-345.
7. Cavaco S, Martins da Silva A, Santos E, et al. Are cognitive and olfactory dysfunctions in neuropsychiatric lupus erythematosus dependent on anxiety or depression? J Rheumatol 2012; 39: 770-776.
8. Schmeding A, Schneider M,. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2013; 27: 363-375.
9. Lau CS, Mak A,. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009; 5: 400-404.
10. Kasitanon N, Achsavalertsak U, Maneeton B, et al. Associated factors and psychotherapy on sleep disturbances in systemic lupus erythematosus. Lupus 2013; 22: 1353-1360.
11. Shen B, Feng G, Tang W, et al. The quality of life in Chinese patients with systemic lupus erythematosus is associated with disease activity and psychiatric disorders: A path analysis. Clin Exp Rheumatol 2014; 32: 101-107.
12. Tam LS, Wong A, Mok VC, et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 1038-1045.
13. Stoll T, Kauer Y, Büchi S, Klaghofer R, Sensky T, Villiger PM,. Prediction of depression in systemic lupus erythematosus patients using SF-36 Mental Health scores. Rheumatology (Oxford) 2001; 40: 695-698.
14. Tench CM, McCurdie I, White PD, D'Cruz DP,. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 1249-1254.
15. Dönmez S, Pamuk ÖN, Ümit EG, Top MÅ,. Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: A comparative study. Clin Exp Rheumatol 2012; 30 (6 Suppl 74): 65-69.
16. Torrente-Segarra V, Carbonell-Abelló J, Castro-Oreiro S, Manresa Domínguez JM,. Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 2010; 28 (6 Suppl 63): S22-S26.
17. García Morales M, Callejas Rubio JI, Peralta-Ramírez MI, et al. Impaired sexual function in women with systemic lupus erythematosus: A cross-sectional study. Lupus 2013; 22: 987-995.
18. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004; 43: 1580-1586.
19. Mok CC, Chan KL, Cheung EF, Yip PS,. Suicidal ideation in patients with systemic lupus erythematosus: Incidence and risk factors. Rheumatology (Oxford) 2014; 53: 714-721.
20. Mak A, Tang CS, Chan MF, Cheak AA, Ho RC,. Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus. Clin Rheumatol 2011; 30: 795-803.
21. Waldheim E, Elkan AC, Pettersson S, et al. Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. Lupus 2013; 22: 1118-1127.
22. Friedman AW, Tewi MB, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: XV. Prevalence and correlates of fibromyalgia. Lupus 2003; 12: 274-279.
23. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfá E, Neto FL,. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 2007; 48: 14-19.
24. Walker SE, Smarr KL, Parker JC, Weidensaul DN, Nelson W, McMurray RW,. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine. Lupus 2000; 9: 527-533.
25. Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 695-700.
26. Shortall E, Isenberg D, Newman SP,. Factors associated with mood and mood disorders in SLE. Lupus 1995; 4: 272-279.
27. Jarpa E, Babul M, Calderón J, et al. Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 2011; 20: 58-66.
28. Lim L, Ron MA, Ormerod IE, et al. Psychiatric and neurological manifestations in systemic lupus erythematosus. Q J Med 1988; 66: 27-38.
29. Kheirandish M, Faezi ST, Paragomi P, et al. Prevalence and severity of depression and anxiety in patients with systemic lupus erythematosus: An epidemiologic study in Iranian patients. Mod Rheumatol 2015; 25: 405-409.
30. Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S,. Depression and systemic lupus erythematosus: A systematic review. Lupus 2013; 22: 409-416.
31. Wehry AM, McNamara RK, Adler CM, et al. Neurostructural impact of co-occurring anxiety in pediatric patients with major depressive disorder: A voxel-based morphometry study. J Affect Disord 2014; 171: 54-59.
32. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
33. Härter M, Woll S, Wunsch A, Bengel J, Reuter K,. Screening for mental disorders in cancer, cardiovascular and musculoskeletal diseases. Comparison of HADS and GHQ-12. Soc Psychiatry Psychiatr Epidemiol 2006; 41: 56-62.
34. Lam CL, Pan PC, Chan AW, Chan SY, Munro C,. Can the Hospital Anxiety and Depression (HAD) Scale be used on Chinese elderly in general practice? Fam Pract 1995; 12: 149-154.
35. Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992; 19: 608-611.
36. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
37. Field A,. Regression. In: Discovering statistics using SPSS, 3rd ed. London: SAGE, 2005, pp. 197-263.
38. Karol DE, Criscione-Schreiber LG, Lin M, Clowse ME,. Depressive symptoms and associated factors in systemic lupus erythematosus. Psychosomatics 2013; 54: 443-450.
39. Aldar H, Lapa AT, Bellini B, et al. Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus. Lupus 2012; 21: 1225-1231.
40. Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, Khairy W, Mahmoud RM,. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1377-1385.
41. Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: A role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004; 6: R366-R372.
42. Postal M, Peliçari KO, Sinicato NA, Marini R, Costallat LT, Appenzeller S,. Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus. Cytokine 2013; 61: 785-791.
43. Mak A, Tang CS, Ho RC,. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 2013; 22: 254-261.
44. Maneeton B, Maneeton N, Louthrenoo W,. Prevalence and predictors of depression in patients with systemic lupus erythematosus: A cross-sectional study. Neuropsychiatr Dis Treat 2013; 9: 799-804.
45. Mok CC, Lau CS, Wong RW,. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766-771.
46. Holloway L, Humphrey L, Heron L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: A review of content validity, face validity and psychometric performance. Health Qual Life Outcomes 2014; 12: 116-116.
47. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E,. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433.
48. Waheed A, Hameed K, Khan AM, Syed JA, Mirza AI,. The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan. J Pak Med Assoc 2006; 56: 243-247.